Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YAPPETIZER: Zoledronate and Atorvastatin in TNBC
NCT03358017Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid, atorvastatin in triple-negative breast cancer (TNBC), sponsored by Mario Negri Institute for Pharmacological Research. Started Mar 2018; status: completed.
02
Drugs
zoledronic acidatorvastatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03358017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358017.